IN THE CLAIMS:

Claims 1-38 (**cancelled**).

Claim 39 (**currently amended**): A compound of the formula II:

(II) 

wherein:

ring C is a 9 or 10-membered heteroaromatic ~~an 8, 9, 10, 12 or 13-membered~~ bicyclic ~~or tricyclic~~ moiety ~~which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and~~ which contains 1-3 heteroatoms selected independently from O, N and S;

Zb is -O- or -S-;

n is an integer from 0 to 5;

R^2 represents hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl, $-NR^3R^4$ (wherein R^3 and R^4, which may be the same or different, each represents hydrogen or C_{1-3}alkyl),

or R^2 represents a group R^5X^1-, wherein X^1 represents a direct bond, -O-, $-CH_2$-, -OC(O)-, -C(O)-, -S-, -SO-, $-SO_2$-, $-NR^6C(O)$-, $-C(O)NR^7$-, $-SO_2NR^8$-, $-NR^9SO_2$- or $-NR^{10}$- (wherein R^6, R^7, R^8, R^9 and R^{10} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl), and R^5 is selected from one of the following twenty-two groups:

1) hydrogen, oxiranylC_{1-4}alkyl or C_{1-5}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C_{1-5}alkyl$X^2C(O)R^{11}$ (wherein X^2 represents -O- or -NR^{12}- (in which R^{12} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{11} represents C_{1-3}alkyl, -$NR^{13}R^{14}$ or -OR^{15} (wherein R^{13}, R^{14} and R^{15} which may be the same or different each represents hydrogen, C_{1-5}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

3) C_{1-5}alkylX^3R^{16} (wherein X^3 represents -O-, -S-, -SO-, -SO_2-, -OC(O)-, -NR^{17}C(O)-, -C(O)NR^{18}-, -SO_2NR^{19}-, -$NR^{20}SO_2$- or -NR^{21}- (wherein R^{17}, R^{18}, R^{19}, R^{20} and R^{21} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{16} represents hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl));

4) C_{1-5}alkylX^4C_{1-5}alkylX^5R^{22} (wherein X^4 and X^5 which may be the same or different are each -O-, -S-, -SO-, -SO_2-, -NR^{23}C(O)-, -C(O)NR^{24}-, -SO_2NR^{25}-, -$NR^{26}SO_2$- or -NR^{27}- (wherein R^{23}, R^{24}, R^{25}, R^{26} and R^{27} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{22} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

5) R^{28} (wherein R^{28} is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl,

C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl));

6) C_{1-5}alkylR^{28} (wherein R^{28} is as defined herein);

7) C_{2-5}alkenylR^{28} (wherein R^{28} is as defined herein);

8) C_{2-5}alkynylR^{28} (wherein R^{28} is as defined herein);

9) R^{29} (wherein R^{29} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, C_{1-4}hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C(O)N$R^{30}R^{31}$, -NR^{32}C(O)R^{33} (wherein R^{30}, R^{31}, R^{32} and R^{33}, which may be the same or different, each represents hydrogen, C_{1-4}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl));

10) C_{1-5}alkylR^{29} (wherein R^{29} is as defined herein);

11) C_{2-5}alkenylR^{29} (wherein R^{29} is as defined herein);

12) C_{2-5}alkynylR^{29} (wherein R^{29} is as defined herein);

13) C_{1-5}alkylX^6R^{29} (wherein X^6 represents -O-, -S-, -SO-, -SO_2-, -NR^{34}C(O)-, -C(O)NR^{35}-, -SO_2NR^{36}-, -N$R^{37}SO_2$- or -NR^{38}- (wherein R^{34}, R^{35}, R^{36}, R^{37} and R^{38} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

14) C_{2-5}alkenylX^7R^{29} (wherein X^7 represents -O-, -S-, -SO-, -SO_2-, -NR^{39}C(O)-, -C(O)NR^{40}-, -SO_2NR^{41}-, -N$R^{42}SO_2$- or -NR^{43}- (wherein R^{39}, R^{40}, R^{41}, R^{42} and R^{43} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

15) C_{2-5}alkynylX^8R^{29} (wherein X^8 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{44}C(O)-$, $-C(O)NR^{45}-$, $-SO_2NR^{46}-$, $-NR^{47}SO_2-$ or $-NR^{48}-$ (wherein R^{44}, R^{45}, R^{46}, R^{47} and R^{48} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

16) C_{1-4}alkylX^9C_{1-4}alkylR^{29} (wherein X^9 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{49}C(O)-$, $-C(O)NR^{50}-$, $-SO_2NR^{51}-$, $-NR^{52}SO_2-$ or $-NR^{53}-$ (wherein R^{49}, R^{50}, R^{51}, R^{52} and R^{53} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

17) C_{1-4}alkylX^9C_{1-4}alkylR^{28} (wherein X^9 and R^{28} are as defined herein);

18) C_{2-5}alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

19) C_{2-5}alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

20) C_{2-5}alkenylX^9C_{1-4}alkylR^{28} (wherein X^9 and R^{28} are as defined herein);

21) C_{2-5}alkynylX^9C_{1-4}alkylR^{28} (wherein X^9 and R^{28} are as defined herein); and

22) C_{1-4}alkyl$R^{54}(C_{1-4}\text{alkyl})_q(X^9)_rR^{55}$ (wherein X^9 is as defined herein, q is 0 or 1, r is 0 or 1, and R^{54} and R^{55} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group $-(-O-)_f(C_{1-4}\text{alkyl})_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S

and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the proviso that R^{54} cannot be hydrogen);

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in R^5X^1- may bear one or more substituents selected from hydroxy, halogeno and amino;

R^1 represents hydrogen, oxo, halogeno, hydroxy, C_{1-4}alkoxy, C_{1-4}alkyl, C_{1-4}alkoxymethyl, C_{1-4}alkanoyl, C_{1-4}haloalkyl, cyano, amino, C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-3}alkanoyloxy, nitro, C_{1-4}alkanoylamino, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulphanyl, C_{1-4}alkylsulphinyl, C_{1-4}alkylsulphonyl, carbamoyl, N-C_{1-4}alkylcarbamoyl, N,N-di(C_{1-4}alkyl)carbamoyl, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl, N,N-di(C_{1-4}alkyl)aminosulphonyl, N-(C_{1-4}alkylsulphonyl)amino, N-(C_{1-4}alkylsulphonyl)-N-(C_{1-4}alkyl)amino, N,N-di(C_{1-4}alkylsulphonyl)amino, a C_{3-7}alkylene chain joined to two ring C carbon atoms, C_{1-4}alkanoylaminoC_{1-4}alkyl, carboxy,

or R^1 represents a group $R^{56}X^{10}$, wherein X^{10} represents a direct bond, -O-, -CH_2-, -OC(O)-, -C(O)-, -S-, -SO-, -SO_2-, -NR^{57}C(O)-, -C(O)NR^{58}-, -SO_2NR^{59}-, -$NR^{60}SO_2$- or -NR^{61}- (wherein R^{57}, R^{58}, R^{59}, R^{60} and R^{61} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl), and R^{56} is selected from one of the following twenty-two groups:

1) hydrogen, oxiranylC_{1-4}alkyl or C_{1-5}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C_{1-5}alkylX^{11}C(O)R^{62} (wherein X^{11} represents -O- or -NR^{63}- (in which R^{63} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{62} represents C_{1-3}alkyl, -$NR^{64}R^{65}$ or -OR^{66} (wherein R^{64}, R^{65} and R^{66} which may be the same or different each represents hydrogen, C_{1-5}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

3) C_{1-5}alkyl$X^{12}R^{67}$ (wherein X^{12} represents -O-, -S-, -SO-, -SO_2-, -OC(O)-, -NR^{68}C(O)-, -C(O)NR^{69}-, -SO_2NR^{70}-, -$NR^{71}SO_2$- or -NR^{72}- (wherein R^{68}, R^{69}, R^{70}, R^{71} and R^{72} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{67} represents hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and

C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl));

4) C_{1-5}alkyl$X^{13}C_{1-5}$alkyl$X^{14}R^{73}$ (wherein X^{13} and X^{14} which may be the same or different are each -O-, -S-, -SO-, -SO_2-, -$NR^{74}C(O)$-, -$C(O)NR^{75}$-, -SO_2NR^{76}-, -$NR^{77}SO_2$- or -NR^{78}- (wherein R^{74}, R^{75}, R^{76}, R^{77} and R^{78} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{73} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

5) R^{79} (wherein R^{79} is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl));

6) C_{1-5}alkylR^{79} (wherein R^{79} is as defined herein);

7) C_{2-5}alkenylR^{79} (wherein R^{79} is as defined herein);

8) C_{2-5}alkynylR^{79} (wherein R^{79} is as defined herein);

9) R^{80} (wherein R^{80} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms

selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, C_{1-4}hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $-C(O)NR^{81}R^{82}$, $-NR^{83}C(O)R^{84}$ (wherein R^{81}, R^{82}, R^{83} and R^{84}, which may be the same or different, each represents hydrogen, C_{1-4}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and a group $-(-O-)_f(C_{1-4}alkyl)_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl));

10) C_{1-5}alkylR^{80} (wherein R^{80} is as defined herein);

11) C_{2-5}alkenylR^{80} (wherein R^{80} is as defined herein);

12) C_{2-5}alkynylR^{80} (wherein R^{80} is as defined herein);

13) C_{1-5}alkyl$X^{15}R^{80}$ (wherein X^{15} represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{85}C(O)-$, $-C(O)NR^{86}-$, $-SO_2NR^{87}-$, $-NR^{88}SO_2-$ or $-NR^{89}-$ (wherein R^{85}, R^{86}, R^{87}, R^{88} and R^{89} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{80} is as defined herein);

14) C_{2-5}alkenyl$X^{16}R^{80}$ (wherein X^{16} represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{90}C(O)-$, $-C(O)NR^{91}-$, $-SO_2NR^{92}-$, $-NR^{93}SO_2-$ or $-NR^{94}-$ (wherein R^{90}, R^{91}, R^{92}, R^{93} and R^{94} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{80} is as defined herein);

15) C_{2-5}alkynyl$X^{17}R^{80}$ (wherein X^{17} represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{95}C(O)-$, $-C(O)NR^{96}-$, $-SO_2NR^{97}-$, $-NR^{98}SO_2-$ or $-NR^{99}-$ (wherein R^{95}, R^{96}, R^{97}, R^{98} and R^{99} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{80} is as defined herein);

16) C_{1-4}alkyl$X^{18}C_{1-4}$alkylR^{80} (wherein X^{18} represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{100}C(O)-$, $-C(O)NR^{101}-$, $-SO_2NR^{102}-$, $-NR^{103}SO_2-$ or $-NR^{104}-$ (wherein R^{100}, R^{101}, R^{102}, R^{103} and R^{104} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{80} is as defined herein);

17) C_{1-4}alkyl$X^{18}C_{1-4}$alkylR^{79} (wherein X^{18} and R^{79} are as defined herein);

18) C_{2-5}alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

19) C_{2-5}alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

20) C_{2-5}alkenyl$X^{18}C_{1-4}$alkylR^{79} (wherein X^{18} and R^{79} are as defined herein);

21) C_{2-5}alkynyl$X^{18}C_{1-4}$alkylR^{79} (wherein X^{18} and R^{79} are as defined herein); and

22) C_{1-4}alkyl$R^{105}(C_{1-4}alkyl)_x(X^{18})_yR^{106}$ (wherein X^{18} is as defined herein, x is 0 or 1, y is 0 or 1, and R^{105} and R^{106} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl) with the proviso that R^{105} cannot be hydrogen);

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in $R^{56}X^{10}$- may bear one or more substituents selected from hydroxy, halogeno and amino;

R^{2a} represents hydrogen, halogeno, C_{1-3}alkyl, trifluoromethyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl, -$NR^{3a}R^{4a}$ (wherein R^{3a} and R^{4a}, which may be the same or different, each represents hydrogen or C_{1-3}alkyl), or $R^{5a}(CH_2)_{za}X^{1a}$ (wherein R^{5a} is a 4-, 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno,

cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl), za is an integer from 0 to 4 and X^{1a} represents a direct bond, -O-, -CH_2-, -S-, -SO-, -SO_2-, -NR^{6a}C(O)-, -C(O)NR^{7a}-, -SO_2NR^{8a}-, -$NR^{9a}SO_2$- or -NR^{10a}- (wherein R^{6a}, R^{7a}, R^{8a}, R^{9a} and R^{10a} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

or a salt ~~or prodrug~~ thereof,

with the proviso that R^2 is not hydrogen.

Claim 40 (**previously presented**): A compound of the formula II according to claim 39 wherein R^2 represents hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, amino or R^5X^1-, wherein X^1 is as defined in claim 39 and R^5 is selected from one of the following twenty-two groups:

1) C_{1-4}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from fluoro, chloro and bromo, or C_{2-5}alkyl which may be unsubstituted or substituted with one or more groups selected from hydroxy and amino;
2) C_{2-3}alkylX^2C(O)R^{11} (wherein X^2 is as defined in claim 39 and R^{11} represents -$NR^{13}R^{14}$ or -OR^{15} (wherein R^{13}, R^{14} and R^{15} which may be the same or different are each C_{1-4}alkyl or C_{1-2}alkoxyethyl));
3) C_{2-4}alkylX^3R^{16} (wherein X^3 is as defined in claim 39 and R^{16} is a group selected from C_{1-3}alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl and tetrahydropyranyl, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-2}alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl or tetrahydropyranyl group may bear 1 or 2 substituents selected from oxo,

hydroxy, halogeno, cyano, C_{1-3}cyanoalkyl, C_{1-3}alkyl, C_{1-3}hydroxyalkyl, C_{1-3}alkoxy, C_{1-2}alkoxyC_{1-3}alkyl, C_{1-2}alkylsulphonylC_{1-3}alkyl, C_{1-3}alkoxycarbonyl, C_{1-3}alkylamino, di(C_{1-3}alkyl)amino, C_{1-3}alkylaminoC_{1-3}alkyl, di(C_{1-3}alkyl)aminoC_{1-3}alkyl, C_{1-3}alkylaminoC_{1-3}alkoxy, di(C_{1-3}alkyl)aminoC_{1-3}alkoxy and a group -(-O-)$_f$(C_{1-3}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from C_{1-3}alkyl));

4) C_{2-3}alkylX^4C_{2-3}alkylX^5R^{22} (wherein X^4 and X^5 are as defined in claim 39 and R^{22} represents hydrogen or C_{1-3}alkyl);

5) R^{28} (wherein R^{28} is as defined in claim 39);

6) C_{1-4}alkylR^{110} (wherein R^{110} is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidin-1-yl, azetidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to C_{1-4}alkyl through a carbon atom and which group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-3}cyanoalkyl, C_{1-3}alkyl, C_{1-3}hydroxyalkyl, C_{1-3}alkoxy, C_{1-2}alkoxyC_{1-3}alkyl, C_{1-2}alkylsulphonylC_{1-3}alkyl, C_{1-3}alkoxycarbonyl, C_{1-3}alkylamino, di(C_{1-3}alkyl)amino, C_{1-3}alkylaminoC_{1-3}alkyl, di(C_{1-3}alkyl)aminoC_{1-3}alkyl, C_{1-3}alkylaminoC_{1-3}alkoxy, di(C_{1-3}alkyl)aminoC_{1-3}alkoxy and a group -(-O-)$_f$(C_{1-3}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from C_{1-3}alkyl)) or C_{2-4}alkylR^{111} (wherein R^{111} is a group selected from morpholino, thiomorpholino, azetidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl and piperidino which group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-3}cyanoalkyl, C_{1-3}alkyl, C_{1-3}hydroxyalkyl, C_{1-3}alkoxy, C_{1-2}alkoxyC_{1-3}alkyl, C_{1-2}alkylsulphonylC_{1-3}alkyl, C_{1-3}alkoxycarbonyl, C_{1-3}alkylamino, di(C_{1-3}alkyl)amino, C_{1-3}alkylaminoC_{1-3}alkyl, di(C_{1-3}alkyl)aminoC_{1-3}alkyl, C_{1-3}alkylaminoC_{1-3}alkoxy, di(C_{1-3}alkyl)aminoC_{1-3}alkoxy and a group

-(-O-)$_f$(C_{1-3}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from C_{1-3}alkyl));

7) C_{3-4}alkenylR^{112} (wherein R^{112} represents R^{110} or R^{111} as defined herein);

8) C_{3-4}alkynylR^{112} (wherein R^{112} represents R^{110} or R^{111} as defined herein);

9) R^{29} (wherein R^{29} is as defined in claim 39);

10) C_{1-4}alkylR^{29} (wherein R^{29} is as defined in claim 39);

11) 1-R^{29}prop-1-en-3-yl or 1-R^{29}but-2-en-4-yl (wherein R^{29} is as defined in claim 39 with the proviso that when R^5 is 1-R^{29}prop-1-en-3-yl, R^{29} is linked to the alkenyl group via a carbon atom);

12) 1-R^{29}prop-1-yn-3-yl or 1-R^{29}but-2-yn-4-yl (wherein R^{29} is as defined in claim 39 with the proviso that when R^5 is 1-R^{29}prop-1-yn-3-yl, R^{29} is linked to the alkynyl group via a carbon atom);

13) C_{1-5}alkylX^6R^{29} (wherein X^6 and R^{29} are as defined in claim 39);

14) 1-($R^{29}X^7$)but-2-en-4-yl (wherein X^7 and R^{29} are as defined in claim 39);

15) 1-($R^{29}X^8$)but-2-yn-4-yl (wherein X^8 and R^{29} are as defined in claim 39);

16) C_{2-3}alkylX^9C_{1-3}alkylR^{29} (wherein X^9 and R^{29} are as defined in claim 39);

17) C_{2-3}alkylX^9C_{1-3}alkylR^{28} (wherein X^9 and R^{28} are as defined in claim 39);

18) C_{2-5}alkenyl which may be unsubstituted or which may be substituted with one or more fluorine atoms or with one or two groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

19) C_{2-5}alkynyl which may be unsubstituted or which may be substituted with one or more fluorine atoms or with one or two groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

20) C_{2-4}alkenylX^9C_{1-3}alkylR^{28} (wherein X^9 and R^{28} are as defined in claim 39);

21) C_{2-4}alkynylX^9C_{1-3}alkylR^{28} (wherein X^9 and R^{28} are as defined in claim 39); and

22) C_{1-3}alkylR^{54}(C_{1-3}alkyl)$_q$(X^9)$_r$$R^{55}$ (wherein X^9, q, r, R^{54} and R^{55} are as defined in claim 39);

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in R^5X^1- may bear one or more substituents selected from hydroxy, halogeno and amino.

Claim 41 (**previously presented**): A compound according to claim 39 wherein Zb is -O-.

Claim 42 (**cancelled**).

Claim 43 (**previously presented**): A compound according to claim 39 wherein R^1 represents oxo, halogeno, hydroxy, C_{1-2}alkoxy, C_{1-2}alkyl, C_{1-2}alkoxymethyl, C_{2-3}alkanoyl, C_{1-2}haloalkyl, cyano, amino, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{2-3}alkanoyloxy, nitro, C_{2-3}alkanoylamino, C_{1-2}alkoxycarbonyl, C_{1-2}alkylsulphanyl, C_{1-2}alkylsulphinyl, C_{1-2}alkylsulphonyl, carbamoyl, N-C_{1-2}alkylcarbamoyl, N,N-di(C_{1-2}alkyl)carbamoyl, aminosulphonyl, N-C_{1-2}alkylaminosulphonyl, N,N-di(C_{1-2}alkyl)aminosulphonyl, N-(C_{1-2}alkylsulphonyl)amino, N-(C_{1-2}alkylsulphonyl)-N-(C_{1-2}alkyl)amino or a C_{3-7}alkylene chain joined to two ring C carbon atoms.

Claim 44 (**previously presented**): A compound according to claim 39 wherein n is 0, 1 or 2.

Claim 45 (**presently amended**): A compound according to claim 39 wherein Zb is -O-, with the proviso that R^2 is not ~~hydrogen,~~ substituted or unsubstituted C_{1-5}alkyl, halogeno, C_{1-5}alkoxy, C_{2-5}alkenyl, phenoxy or phenylC_{1-5}alkoxy.

Claim 46 (**previously presented**): A compound according to claim 39 selected from 6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-4-(quinolin-7-yloxy)quinazoline, 7-(3-(1,1-dioxothiomorpholino)propoxy)-6-methoxy-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)-4-(quinolin-7-yloxy)quinazoline,

4-(4-chloroquinolin-7-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-4-(4-methylquinolin-7-yloxy) quinazoline,

6-methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-7-((1-(2-methylsulphonylethyl)piperidin-4-yl)methoxy)-4-(quinolin-7-yloxy)quin azoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy) quinazoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,

6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy) quinazoline,

6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline,

(*R*,*S*)-4-(3-fluoroquinolin-7-yloxy)-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy) quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-methylsulphonylpropoxy)quinazoline,

7-(3-N,N-dimethylaminopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(2-morpholinoethoxy)ethoxy)quinazoline,

7-(2-(N,N-diethylamino)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-7-(3-piperidinopropoxy)-4-(quinolin-7-yloxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(2-(piperidin-1-yl)ethoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(2-(1*H*-1,2,4-triazol-1-yl)ethoxy)quinazoline,

6-methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline,

7-(3-(methylsulphonyl)propoxy)-4-(2-methylindol-5-yloxy)quinazoline,

7-(3-(N,N-dimethylamino)propoxy)-4-(2,3-dimethylindol-5-yloxy)-6-methoxy-quinazoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-3-ylmethoxy) quinazoline,

7-(2-(N,N-diethylamino)ethoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(piperidin-2-yl)ethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazoline,
4-(indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
7-(3-(ethylsulphonyl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline,
7-(2-hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
7-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methylamino)ethoxy)quinazoline, and
7-(2-hydroxy-3-(isopropylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
or a salt thereof.

Claim 47 (**previously presented**): A compound according to claim 39 selected from
6-methoxy-7-(3-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline,
4-(indol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-methylsulphonylpropoxy)quinazoline,
7-((1-cyanomethyl)piperidin-4-ylmethoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-methylpiperidin-3-ylmethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methyl-N-(4-pyridyl)amino)ethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(1*H*-1,2,4-triazol-1-yl)ethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

6-methoxy-7-(1-(2-methoxyethyl)piperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-((2-(2-pyrrolidin-1-ylethyl)carbamoyl)vinyl) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-(4-methypiperazin-1-yl)propoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(piperidin-4-yloxy)ethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methyl-N-methylsulphonylamino)ethoxy)qui nazoline,

7-(2-(1-(2-cyanoethyl)piperidin-4-yloxy)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

4-(2-methylindol-5-yloxy)-7-(3-(pyrrolidin-yl)propoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(3-(1,1-dioxothiomorpholino)propoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)quinazoline,

7-(3-(N,N-dimethylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

7-(3-(N,N-diethylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

7-(3-(1,1-dioxothiomorpholino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(4-pyridyloxy)ethoxy)quinazoline,

4-(indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

7-(1-(2-methoxyethyl)piperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy)quinazoline,

7-(2-hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

7-(2-(1-(2-methoxyethyl)piperidin-4-yl)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

7-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

7-(3-(N,N-diethylamino)-2-hydroxypropoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

7-(3-(1,1-dioxothiomorpholino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(4-pyridyloxy)ethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

(2*R*)-6-methoxy-(2-methyl-1*H*-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy) quinazoline,

(5*R*)-6-methoxy-4-(2-methyl-1*H*-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy) quinazoline,

4-(4-bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-(2-(pyrrolidin-1-yl)ethyl)-piperidin-4-ylmethoxy)quinazoline,

(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*R*)-7-(2-hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*R*)-7-(2-hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*S*)-7-(2-hydroxy-3-((N,N-diisopropyl)amino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*S*)-7-(2-hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*R*)-7-(2-hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy) quinazoline,

(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(3-methylindol-5-yloxy) quinazoline,

(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

(2*R*)-7-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-(2-morpholinoethyl)piperidin-4-ylmethoxy) quinazoline,

4-(3-fluoro-quinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

4-(3-fluoro-quinolin-7-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-4-(1*H*-pyrrolo[2,3-*b*]pyridin-5-yloxy) quinazoline,
(2*S*)-6-methoxy-(2-methyl-1*H*-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy) quinazoline, and
4-(6-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy) quinazoline,
or a salt thereof.

Claim 48 (**previously presented**): A compound according to claim 39 selected from 6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
4-(6-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy) quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy) quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy) quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline, and
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy) quinazoline,
or a salt thereof.

Claim 49 (**previously presented**): A compound according to claim 39 in the form of a pharmaceutically acceptable salt.

Claim 50 **(cancelled)**.

Claims 51 **(currently amended)**: A pharmaceutical composition which comprises as active ingredient a compound of formula II~~I~~ or a pharmaceutically acceptable salt thereof according to any one of claims 39-41, 43-48 and 61 ~~claim 39~~ in association with a pharmaceutically acceptable excipient or carrier.

Claims 52-60 **(cancelled)**.

Claim 61 **(previously presented)**: A compound according to claim 39 wherein ring C is selected from indolyl and quinolinyl.

Claim 62 **(cancelled).**

Claim 63 **(new)**: A method for inhibiting VEGF receptor tyrosine kinase activity in a warm-blooded animal in need thereof comprising administering to said animal an inhibiting amount of a compound of the formula II as defined in any one of claims 39-41, 43-48 and 61 or a pharmaceutically acceptable salt thereof.